Lakefront Biotherapeutics (GLPGF) Other Non Operating Income (2014 - 2025)

Lakefront Biotherapeutics (GLPGF) has reported Other Non Operating Income for 11 consecutive years, with $17.2 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Other Non Operating Income fell 8.92% year-over-year to $17.2 million in Q4 2025; TTM through Dec 2025 was $51.0 million, a 47.31% decrease from a year earlier, with the FY2025 full-year figure at $51.1 million, down 47.22% from the prior year.
• Other Non Operating Income was $17.2 million for Q4 2025 at Lakefront Biotherapeutics, up from $10.8 million in the prior quarter.
• Over five years, Other Non Operating Income peaked at $43.7 million in Q1 2021 and troughed at -$76.0 million in Q4 2021.
• A 5-year average of $11.1 million and a median of $15.3 million in 2025 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income slumped 109.0% in 2022 and surged 2702.26% in 2023, its largest moves.
• Over 5 years, Other Non Operating Income stood at -$76.0 million in 2021, then jumped by 116.25% to $12.3 million in 2022, then soared by 105.69% to $25.4 million in 2023, then slipped by 25.51% to $18.9 million in 2024, then decreased by 8.92% to $17.2 million in 2025.
• The last three Other Non Operating Income figures came in at $17.2 million (Q4 2025), $10.8 million (Q3 2025), and $10.6 million (Q2 2025), per Business Quant data.